Free testosterone and malignant melanoma risk in men: prospective analyses of testosterone and SHBG with 19 cancers in men and postmenopausal women UK Biobank

Authors

Eleanor L. Watts¹, Aurora Perez-Cornago¹, Anika Knuppel¹, Konstantinos K. Tsilidis^{2,3},

Timothy J. Key¹, Ruth C. Travis¹

Affiliations

¹Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK

²Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece

³Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK

Corresponding Author

Eleanor L. Watts

Email: ellie.watts@ndph.ox.ac.uk

Abstract

We investigated the associations of estimated free and total circulating testosterone and sex hormone-binding globulin (SHBG) with cancer risk in men and postmenopausal women, using a pan-cancer approach, including 19 cancers in UK Biobank.

Risk was estimated using multivariable-adjusted Cox regression in up to 182,608 men and 122,112 postmenopausal women who were cancer-free at baseline. Participants diagnosed with cancer within two years of baseline were excluded. Hazard ratios (HRs) and confidence intervals (CIs) were corrected for regression dilution bias using repeat measurements. We accounted for multiple testing using the false discovery rate.

In men, higher free testosterone was associated with higher risks of melanoma and prostate cancer (HR per 50 pmol/L increase=1.35, 95% CI 1.14-1.61 and 1.10,1.04-1.18, respectively). Higher total testosterone was associated with an elevated risk of liver cancer (HR per 5 nmol/L=2.45,1.56-3.84), and higher SHBG was associated with a higher risk of liver cancer (HR per 10 nmol/L=1.56,1.31-1.87) and a lower risk of prostate cancer (0.93,0.91-0.96); associations with liver cancer were attenuated after excluding early follow-up. In postmenopausal women, higher free and total testosterone and lower SHBG were associated with elevated risks of endometrial (HR per 10 pmol/L=1.59,1.32-1.90; HR per 0.5 nmol/L=1.34,1.18-1.52 and HR per 25 nmol/L=0.78,0.67-0.91, respectively) and breast cancer (1.32,1.22-1.43;1.24,1.17-1.31 and 0.88,0.83-0.94, respectively).

We report a novel association of free testosterone with malignant melanoma in men; our findings also support known associations between sex hormones and risks for prostate, breast and endometrial cancers. The association with liver cancer in men may be attributable to reverse causation.

Introduction

It is well-established that men have a higher risk of most non–sex-specific cancers than women(1,2). While some of these differences are due to lifestyle factors, there is also evidence that sex hormones are involved in the development of several cancers(3-6). However, aside from prostate(7-9), breast(9-11), and endometrial(9,12,13) cancers, previous population-based observational with hormone measurements have had limited power to assess associations with other cancer sites(4,5,14). Current evidence of associations with other cancers is largely based on animal models and tumor cell lines(15-17), or investigated indirectly via associations with self-reported menstrual and reproductive factors in women(18,19).

There are large sex differences in the regulation and quantities of serum androgens in men and postmenopausal women, therefore associations with disease risk should be assessed separately(20). In men, testosterone is primarily synthesised by the testes and serum concentrations of free testosterone are regulated by the hypothalamic-pituitary-gonadal (HPG) axis(21); while in women, testosterone is synthesised by the adrenal glands and ovaries, and the HPG axis is thought to have little direct effect in the regulation of testosterone concentrations(22). In both sexes, sex hormone-binding globulin (SHBG) is primarily synthesised by the liver and is secreted into the bloodstream, where it tightly binds to sex hormones and modulates their bioavailability(23).

In this paper, we aimed to examine the associations of serum concentrations of free testosterone, total testosterone and SHBG with the diagnosis of 19 cancers in a cohort of 182,600 men and 122,100 postmenopausal women in the UK Biobank, who were cancer-free >2 years from study baseline. This comprehensive pan-cancer approach, using standardised

hormone and cancer endpoint analyses, enables the comparison of effect estimates and the exploration of the specificity of our findings.

Materials and methods

Study design

UK Biobank is a prospective cohort for public health research. Details of the study protocol and data collection are available online (<u>http://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-Biobank-Protocol.pdf</u>) and elsewhere(24,25).

In brief, all participants were registered with the UK National Health Service (NHS) and lived within 40 km of one of the UK Biobank assessment centres. Approximately 9.2 million people were initially invited to participate. Overall, 503,317 participants aged 40-69 years consented to join the cohort and attended one of 22 assessment centres throughout England, Wales and Scotland between 2006-2010, a participation rate of 5.5%(25).

The UK Biobank study was approved by the North West Multi-Centre Research Ethics Committee (reference number 06/MRE08/65), and at recruitment all participants gave written informed consent to participate and for their health to be followed-up through linkage to electronic medical records.

Baseline assessment

At the baseline assessment visit, participants provided information on a range of sociodemographic, anthropometric, lifestyle, and health-related factors via a self-completed touch-screen questionnaire and a computer assisted personal interview(25).

Blood sampling and biomarker assays

At recruitment, blood sampling was successfully performed in 99.7% of the cohort. Blood was collected in a serum separator tube and shipped to the central processing laboratory in

temperature-controlled boxes at $4^{\circ}C(26)$, then aliquoted and stored in a central working archive at -80°C(27). Serum concentrations of SHBG, testosterone and albumin were attempted in all participants. SHBG and testosterone (Beckman Coulter AU5800) were measured by chemiluminescent immunoassays, and albumin was measured by a colorimetric assay (Beckman Coulter AU5800). Average within-laboratory (total) coefficients of variation for low, medium, and high internal quality control level samples for each biomarker ranged from 2.1-8.3%.

Participants with total testosterone below the limit of detection were assigned a serum concentration of 0.26 nmol/L (3/4 of the lower limit of detection) (n=16 men and 25,253 postmenopausal women).

Serum insulin-like growth factor-I (IGF-I), glycated haemoglobin (HbA1c) and C-reactive protein (CRP) concentrations were also assayed in serum from blood collected at study baseline. Full details of the assay methods and quality assurance protocols are available online (https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/serum_biochemistry.pdf).

Free testosterone calculation

In the circulation, testosterone is bound to SHBG and albumin. Approximately 2% of total testosterone circulates unbound or "free" and is postulated to be biologically active(23). Free testosterone concentrations were estimated using a formula based on the law of mass action and measured total testosterone, SHBG and albumin concentrations(7,28).

Repeat measurements

Repeat assessments were completed in 20,000 individuals. Participants who lived within a 35 km radius were invited via email to attend a repeat assessment clinic at the UK Biobank Coordinating Centre in Stockport between August 2012 and June 2013, with a response rate of 21%(29).

Participant follow-up

Cancer registration data were provided via record linkage to the NHS Central Register and obtained via NHS Digital, until the censoring date (31st March 2016 in England and Wales and 31st October 2015 in Scotland).

Endpoints were defined as the first incident cancer diagnosis, or cancer recorded on death certificate if not previously diagnosed with cancer. Cancers were coded using the International Classification of Diseases Tenth revision code (ICD-10)(30) and we restricted analyses to cancers with a minimum of 100 recorded cases in men, and 100 cases for female only cancers (for consistency across sexes): lip, oral and pharynx (C00-14), oesophagus (C15), adenocarcinoma of oesophagus (C15, morphology codes ICD-O-3 8140-8573), stomach (C16), colorectum (C18-20) including colon (C18) and rectum (including rectosigmoid junction; C19-20), liver (C22), pancreas (C25), lung (C34), malignant melanoma (C43), mesothelioma (C45), female breast (C50), endometrial (C54.1), ovarian (C56), prostate (C61), kidney (C64-65), bladder (C67), brain (C71), non-Hodgkin lymphoma (NHL) (C82-85), multiple myeloma (C90), and leukemia (C91-95), and the NHL subtype diffuse NHL (C83). Person-years were calculated from the date of recruitment to the date of the first cancer registration, death, loss to follow-up, or censoring date, whichever occurred first.

Exclusion criteria

Our analytical dataset included up to 182,608 men and 122,112 postmenopausal women (Supplementary Figure S1). We excluded 27,170 participants with prevalent cancer (except C44: non-melanoma skin cancer), 32,563 with no blood measurement data available or who had biomarker measurements that did not pass quality control procedures(31), 1,533 who were missing BMI measurement data and 22,697 who were diabetic at baseline (self-

reported). We also excluded 6,070 participants who were diagnosed with cancer <2 years from baseline, 2,629 who were taking hormone-related medication at baseline, and 3,843 participants for whom it was not possible to determine genetic sex or whose genetic sex was identified as being different from their reported sex.

In women, we also excluded 66,526 participants who were either premenopausal or unknown (postmenopausal was defined as stopped period, aged >55 years), 12,745 women who were current users of hormone replacement therapy (HRT) or the contraceptive pill, 930 who had prevalent *in situ* breast cancer at study baseline, and 19,786 who reported having a hysterectomy or bilateral oophorectomy at study baseline (Supplementary Figure S1).

Statistical analysis

Cox proportional hazards models were used to estimate the associations with cancer diagnosis, with age as the underlying time variable. Primary analyses were stratified by geographic area (10 UK regions) and age at recruitment (<45, 45-49, 50-54, 55-59, 60-64, \geq 65 years), and adjusted for Townsend deprivation score (fifths, unknown (0.1%)), education level (college or university degree/vocational qualification, national examination at ages 17/18, national examination at age 16, other qualification or unknown (19.0%)), racial/ethnic group (white, Asian, black, mixed background and other, and unknown (1.2%)), height (<170, \geq 170–<175, \geq 175–<180, \geq 180 cm, and unknown (0.1%), for men; and <160, \geq 160–<165, \geq 165–<170, \geq 170 cm, and unknown (0.02%), for women), BMI (<25, \geq 25–<30, \geq 30–<35, \geq 35 kg/m²), cigarette smoking (never, former, current light smoker (1-<15 cigarettes per day), current heavy smoker (\geq 15 cigarettes per day), current (number of cigarettes per day unknown), and smoking status unknown (0.5%)), alcohol consumption (non-drinkers, <1-<10, \geq 10-<20, \geq 20 g ethanol/day, unknown (0.6%)), and total physical activity (<10, 10-19, 20-39, 40-59, \geq 60 metabolic equivalent of task hours per week, and unknown (0.6%)). For

postmenopausal women, we additionally adjusted for past HRT use (never, ever), past oral contraceptive pill use (never, ever), parity and age at first birth (nulliparous; 1-2, <25; 1-2, 25-29; 1-2, \geq 30; 1-2, unknown; \geq 3, <25; \geq 3, 25-29; \geq 3, \geq 30 years, unknown (16.0%)), age at menarche (<12, 12-13, \geq 14 years, unknown (2.9%)), and age at menopause (<45, 45-49, 50-54, \geq 55 years, unknown (14.9%)). Adjustment covariates were defined *a priori* based on previous analyses of UK Biobank data(32).

Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using the median value within each fourth and calibrated to allow risk estimates on a continuous scale (per 50 pmol/L, per 5 nmol/L and 10 nmol/L increments for free testosterone, total testosterone and SHBG, respectively for men and per 10 pmol/L, per 0.5 nmol/L and 25 nmol/L, respectively for postmenopausal women; these increments were chosen based on the sex-specific hormone standard deviations [SDs]).

Measurement error and within person variability using single measures at baseline leads to under-estimation of risk (i.e. regression dilution bias)(33). Estimates for trend were corrected for regression dilution bias by assigning the median values from the fourths of blood biomarker concentrations measured in the repeat blood sample for the subcohort who attended the repeat assessment (up to 7,669 men and 4,568 postmenopausal women, median of 4.3 years after first blood collection(34)) to women grouped by fourths of hormone concentrations measured at study baseline(35), excluding participants who were diagnosed with cancer between baseline and repeat assessment (up to 132 men and 48 women).

In the categorical analyses, biomarker measurements were categorised into fourths and HRs were calculated relative to the lowest fourth of each blood parameter. The variance of the log risk in each group was calculated (from the variances and covariances of the log risk) and

used to obtain group-specific 95% CIs, which enable comparisons across different exposure categories(36).

Sensitivity analyses

Subgroup analyses

Subgroup analyses for incident cancer were examined with participants categorised according to: i) time from blood collection to diagnosis (>2 -≤4.7, >4.7 years) ii) age at diagnosis (≤65, >65 years), and iii), age at blood collection (≤60, >60 years), categories were based on the median values within this sample. Heterogeneity in the associations for case-specific variables (i.e. time to diagnosis and age at diagnosis) was examined using stratified Cox models based on competing risks, comparing the risk coefficients and standard errors in the two subgroups, and testing with a χ^2 for heterogeneity. For age at blood collection, heterogeneity was assessed using a χ^2 interaction term.

Adjustment for other factors

To assess the role of other biomarkers, we further adjusted the primary analysis for serum IGF-I, HbA1c and CRP concentrations (fourths, unknown). The association of testosterone concentration and melanoma may have been confounded by factors relating to sun exposure and sensitivity, therefore we additionally adjusted for: skin color (very fair, fair, light olive, dark olive, brown/black, missing); hair color (blonde, red, light brown, dark brown, black, missing); skin reaction to sun exposure (get very tanned, moderately tanning, mildly/occasionally tanning, never tanning only burning, missing); and sunburn before age 15 (never, ever, missing).

All analyses were performed using Stata version 14.1 (Stata Corporation, College Station, TX, USA), and figures were plotted in R version 3.6.3. All tests of significance were two-

sided, and P-values <0.05 were considered statistically significant. In the primary analysis, we additionally accounted for multiple testing using false discovery rates (FDR; 48 statistical tests in men and 54 statistical tests in women)(37).

Results

After a mean follow-up of 7.0 years (SD=1), 9,519 men (5.2%) and 5,632 postmenopausal women (4.6%) were diagnosed with any type of malignant cancer (excluding non-melanoma skin cancer, C44).

Table 1 summarises the baseline characteristics of study participants. Mean age at recruitment was 56.1 (SD=8.2) in men and 60.2 years (5.3) in postmenopausal women. Participants who subsequently developed cancer were older, were more likely to smoke and had worse self-rated health at recruitment. Men who were subsequently diagnosed with cancer on average had a slightly lower socioeconomic status, while women who were diagnosed with cancer had a slightly higher socioeconomic status and were more likely to have previously used HRT compared those without a cancer diagnosis (Table 1). Mean and SD values for baseline biomarker measurements are displayed in Table 1.

Associations between testosterone and SHBG concentrations and cancer diagnosis

Men

Serum free testosterone concentration was positively associated with risks of malignant melanoma and prostate cancer (HR per 50 pmol/L increment=1.35, 95% CI 1.14-1.61; P_{trend} =0.0006, and 1.10, 1.04-1.18; P_{trend} =0.002, respectively) and inversely associated with the risk of leukemia (0.77, 0.60-0.99; P_{trend} =0.04) (Figure 1).

Serum total testosterone concentration was positively associated with risks for liver cancer (HR per 5 nmol/L increment=2.45, 1.56-3.84; P_{trend} =0.0001), mesothelioma (1.63, 1.10-2.42; P_{trend} =0.02) and malignant melanoma (1.28, 1.05-1.55; P_{trend} =0.02) (Figure 1).

Serum SHBG concentrations were positively associated with risks of liver (HR per 10 nmol/L increment=1.56, 1.31-1.87; P_{trend} =<0.0001) and stomach cancer (1.21, 1.05-1.40; P_{trend} =0.008) and inversely with risks of prostate (0.93, 0.91-0.96; P_{trend} =<0.0001) and colorectal cancer (0.94, 0.89-0.99; P_{trend} =0.02) (Figure 1).

After accounting for multiple testing, the associations of free testosterone with prostate cancer and melanoma, total testosterone with liver cancer, and SHBG with liver and prostate cancer remained statistically significant.

Postmenopausal women

Serum free testosterone concentration was positively associated with risks of endometrial and breast cancer (HR per 10 pmol/L increment=1.59, 1.32-1.90; P_{trend} <0.0001, and 1.32, 1.22-1.43; P_{trend} <0.0001, respectively), and inversely with risks of multiple myeloma (0.65, 0.43-0.97; P_{trend} =0.03) and NHL (0.76, 0.59-0.99; P_{trend} =0.04) (Figure 2).

Serum total testosterone concentration was positively associated with risks of endometrial (HR per 0.5 nmol/L increment=1.34, 1.18-1.52; P_{trend} <0.0001), breast (1.24, 1.17-1.31; P_{trend} <0.0001), and pancreatic cancer (1.25, 1.01-1.55; P_{trend} =0.04) and inversely with risk of multiple myeloma (0.73. 0.56-0.96; P_{trend} =0.02) (Figure 2).

Serum SHBG concentrations were inversely associated endometrial (HR per 25 nmol/L increment=0.78, 0.67-0.91; P_{trend} =0.001) and breast cancer (0.88, 0.83-0.94; P_{trend} =0.0002) (Figure 2).

After accounting for multiple testing, the associations of free and total testosterone and SHBG with endometrial and breast cancer remained statistically significant.

Results including cancer subtypes, fourths, adjustment models and associations with and without adjustment for regression dilution bias are displayed in Supplementary Tables S1-S6.

Sensitivity analyses

Subgroup analyses

In men, the significant associations between testosterone and cancer diagnosis showed no significant heterogeneity by length of follow-up, age at diagnosis, or age at blood collection (Figure 3 and Supplementary Figures S2-3). There was evidence of heterogeneity in the association of SHBG with liver cancer by length of follow-up; men diagnosed with liver cancer 2-4.7 years from baseline had a higher risk of liver cancer diagnosis in relation to SHBG (HR per 10 nmol/L increment=1.92, 95% CI 1.45-2.55), while the magnitude of this association was smaller in men diagnosed >4.7 years from baseline (1.32, 1.05-1.67; P_{het} =0.04).

In postmenopausal women, associations of testosterone and SHBG showed no significant heterogeneity by length of follow-up, age at diagnosis or age at blood collection (Figure 4 and Supplementary Figures S4-5), with the exception of total testosterone concentration and endometrial cancer by age at diagnosis and age at blood collection; postmenopausal women diagnosed with endometrial cancer aged ≤ 65 years had a larger magnitude of association of total testosterone with endometrial cancer risk (HR per 0.5 nmol/L increment=1.58, 95% CI 1.30-1.91), than women diagnosed aged ≥ 65 years (1.17, 0.98-1.39; P_{het}=0.02) (Supplementary Figure 4). Similarly, women aged ≤ 60 years at blood collection had a larger

magnitude of association (1.67, 1.32-2.12), than women >60 years at baseline (1.22, 1.05-1.42; P_{het} =0.03).

Adjustment for other factors

In men, following further adjustment for IGF-I, HbA1c and CRP, the association of SHBG concentration with colorectal cancer slightly attenuated (HR per 10 nmol/L increment=0.95, 95% CI 0.90-1.00; P_{trend} =0.07) (Supplementary Table S4).

In postmenopausal women, further adjustment for these biomarkers slightly attenuated the association of serum free testosterone with NHL (HR per 10 pmol/L increment=0.78, 95% CI=0.60-1.01; P_{trend} =0.06) (Supplementary Table S5).

The associations of free and total testosterone with melanoma in men were not materially different following further adjustment for sun exposure and sensitivity factors (Supplementary Table S7).

Discussion

This comprehensive analysis of serum free and total testosterone and SHBG concentrations with cancer risk in 182,600 men and 122,100 postmenopausal women shows a novel association of free testosterone with melanoma risk in men. We also confirm previously observed associations with prostate(7-9), breast(9-11), and endometrial(9,12,13) cancer. We additionally report several possible associations with other cancer sites, particularly with SHBG and stomach cancer, but these associations were not statistically significant after accounting for multiple testing.

Associations with incident cancer in men

Higher total and free testosterone concentrations were associated with an increased risk of malignant melanoma. Until now, associations between serum sex hormone concentrations

and melanoma have not been robustly assessed in the context of other large prospective cohort studies (n=41 male melanoma cases)(14). However, it has been observed that men diagnosed with melanoma have a higher risk of developing prostate cancer and *vice versa*, suggesting a common biological cause(38). There is also biological evidence of plausibility; androgens are involved in several skin processes including melanogenesis(15,39); and *in vitro* models implicate a role of androgen signalling in promoting melanoma(15).

We have previously observed associations between free testosterone and prostate cancer risk and an inverse association with SHBG in UK Biobank, and in an international consortium of 20 cohorts (6,933 cases and 12,088 controls)(7,8). These associations are consistent with evidence from two large randomised controlled trials (which aimed to reduce intra-prostatic androgen signalling)(40,41) and a Mendelian randomization study(9). However, testosterone is a determinant of prostate-specific antigen concentrations(42), which are commonly used in the detection of prostate cancer, therefore whether the risk associations might be partly explained by detection bias remains under debate(43,44).

We note the large magnitude of the associations between total testosterone and SHBG and liver cancer, which has been observed previously(3). The liver is integral in sex hormone signalling and metabolism, and synthesis of SHBG. Liver damage often leads to abnormal concentrations of blood biomarkers. For instance, liver fibrosis, which can develop into liver cancer, is associated with higher SHBG concentrations in men(45). Therefore, higher SHBG concentration may be a marker of preclinical disease, which is supported by a marked attenuation of risk estimates when restricting cases to those diagnosed after the median follow-up.

We also observed nominally significant inverse associations between free testosterone and leukemia, total testosterone and mesothelioma, and SHBG and colorectal cancer, and a

positive association between SHBG and stomach cancer risk. However, these associations did not withstand correction for multiple testing. While current evidence of the inverse associations between testosterone and/or SHBG and these cancers is limited, associations between sex hormones and stomach cancer risk have been observed previously(4). Speculatively, this may be due to the role of SHBG in limiting estradiol bioactivity, as estradiol has been shown to reduce the viability and carcinogenic potential of *H. pylori* in animal models(46,47). Nevertheless, we are unable to rule-out the possibility of reverse causation(48) or chance.

Associations with incident cancer in postmenopausal women

In postmenopausal women, we observed positive associations of free and total testosterone with risks for endometrial and breast cancer, while higher SHBG was associated with a lower risk of cancer at these sites. These associations have been observed previously in prospective nested case-control studies(10,12,13) and in Mendelian randomization analyses(9). Associations with breast cancer have also been reported in pooled analyses by an international consortium of 15 cohorts with 3,112 cases and 6,117 controls(11). Higher androgen concentrations might increase the risk of these cancers indirectly, via their conversion to estrogens, which stimulate cell proliferation, increasing the probability of mutations and uncontrolled cell growth(49-51). There is also some evidence that testosterone may affect endometrial and breast cancer risk via androgen receptor signalling(52,53). In epidemiological analyses, when estimates of testosterone and breast cancer risk additionally adjusted for circulating estradiol concentrations the associations somewhat attenuated but remained statistically significant(10), while associations with endometrial cancer attenuated to the null(12,13).

We also observed possible inverse associations of testosterone with multiple myeloma, NHL and pancreatic cancer in postmenopausal women. However, these associations did not withstand correction for multiple testing.

Differences in cancer risk in men vs postmenopausal women

Although men have a greater risk of most cancers in comparison with women(1,2), in this analysis, differences in testosterone and SHBG did not seem to account for this. Men were more likely to smoke, drink alcohol and have hypertension than postmenopausal women, which may indicate a greater importance of sex-differences in lifestyle factors in risk disparities, or differences in risk may be related to other sexual dimorphisms which are independent of sex hormones(2), including greater body size(54).

We did, however, observe a sex-specific association of free testosterone with melanoma. It is possible that these differences are due to the more than ten-fold greater free testosterone concentrations in men. National surveillance data indicate that women have a greater risk of melanoma from the age of puberty until ~40 years old, and from the age of ~50 men have a higher risk(55). This may indicate a relatively greater significance of hormones in premenopausal women, when sex hormone concentrations are markedly different, particularly estradiol, or the importance of other factors such as UV exposure. Large studies or pooling projects which include younger women are needed to investigate this further.

Strengths and limitations

UK Biobank is currently the largest prospective study with hormone data available for nearly the whole cohort, providing a unique opportunity to robustly assess associations of serum testosterone and SHBG concentrations with cancer risk using a comprehensive pan-cancer approach. This greater power improved the precision of our risk estimates and enabled us to investigate associations with less common cancers, and the availability of repeat

measurements enabled us to adjust for regression dilution bias(33). UK Biobank is also a well-characterised study population, and therefore we were able to adjust our risk estimates for a wide range of possible confounders and examine the role of other related biomarkers.

Limitations of the analysis are that tumor characterisation information is not currently available, which may be relevant for the etiology of some cancer sites. We were also underpowered to investigate heterogeneity in the associations, particularly for the less common cancers. The UK Biobank participants are predominantly white and healthier than the sampling population, therefore risk estimates may not be generalizable(25), though this is unlikely to affect the direction of the associations(56). Although all our analyses excluded participants diagnosed with cancer in the first 2 years of follow-up, the follow-up period is not very long and we are not able to completely rule-out the possibility of reverse causation. Although we employed FDR to address the increased risk of chance findings due to the large number of statistical tests, we cannot rule out the possibility of chance findings, particularly in the sensitivity analyses.

SHBG also modulates the bioavailability of other sex hormones including estradiol, which is correlated with testosterone and may independently affect cancer risk via estrogen receptor signalling. However, estradiol concentrations are too low in men and postmenopausal women to obtain accurate data with the assays used in the UK Biobank. Furthermore, 13.8% of postmenopausal women had testosterone concentrations below the limit of detection, this might reduce power and attenuate risk estimates. Free testosterone concentrations were estimated using a commonly-employed formula derived from mass action equations, however the extent to which free testosterone represents the biologically active component of total testosterone remains under debate(57).

In conclusion, our study reports a novel positive association of free testosterone with melanoma in men. Our findings also support established associations of serum testosterone concentrations with prostate cancer risk in men, and with breast and endometrial cancer risk in postmenopausal women. Associations with testosterone were sex and site-specific and therefore do not support a general role of testosterone in cancer risk. Studies with longer follow-up time and pooled datasets including genetic information are needed to further assess associations.

Acknowledgements

We would like to thank Georgina K. Fensom for her contributions to the data analysis. We thank all participants, researchers, and support staff who made the study possible.

Funding

This work is supported by Cancer Research UK (grant numbers C8221/A19170 and C8221/A29017). ELW is supported by the Nuffield Department of Population Health Early Career Research Fellowship. APC is supported by a Cancer Research UK Population Research Fellowship (C60192/A28516) and by the World Cancer Research Fund (WCRF UK), as part of the Word Cancer Research Fund International grant programme (2019/1953). AK is supported by the Wellcome Trust (205212/Z/16/Z). KKT's work in this project is co-financed by Greece and the European Union (European Social Fund-ESF) through the Operational Programme «Human Resources Development, Education and Lifelong Learning 2014- 2020» in the context of the project "Sex steroid hormones and cancer: a molecular epidemiology study" (MIS 5047651).

Data availability

This research has been conducted using the UK Biobank Resource under application numbers

3282 and 24494. All bona fide researchers can apply to use the UK Biobank resource for

health-related research that is in the public interest (https://www.ukbiobank.ac.uk/register-

<u>apply/</u>).

Conflict of interest

The authors have no competing interests to declare.

References

- 1. Scelo G, Li P, Chanudet E, Muller DC. Variability of Sex Disparities in Cancer Incidence over 30 Years: The Striking Case of Kidney Cancer. European Urology Focus **2018**;4:586-90
- 2. Rubin JB, Lagas JS, Broestl L, Sponagel J, Rockwell N, Rhee G, *et al.* Sex differences in cancer mechanisms. Biol Sex Differ **2020**;11:17-
- 3. Lukanova A, Becker S, Hüsing A, Schock H, Fedirko V, Trepo E, *et al.* Prediagnostic plasma testosterone, sex hormone-binding globulin, IGF-I and hepatocellular carcinoma: etiological factors or risk markers? Int J Cancer **2014**;134:164-73
- 4. Petrick JL, Hyland PL, Caron P, Falk RT, Pfeiffer RM, Dawsey SM, *et al.* Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Esophageal/Gastric Cardia Adenocarcinoma Among Men. J Natl Cancer Inst **2018**;111:34-41
- 5. Hyde Z, Flicker L, McCaul KA, Almeida OP, Hankey GJ, Chubb SAP, *et al.* Associations between Testosterone Levels and Incident Prostate, Lung, and Colorectal Cancer. A Population-Based Study. Cancer Epidemiol Biomarkers Prev **2012**;21:1319-29
- 6. Swerdlow AJ, Schoemaker MJ, Higgins CD, Wright AF, Jacobs PA, on behalf of the UKCCG. Cancer Incidence and Mortality in Men with Klinefelter Syndrome: A Cohort Study. J Natl Cancer Inst **2005**;97:1204-10
- 7. Watts EL, Appleby PN, Perez-Cornago A, Bueno-de-Mesquita HB, Chan JM, Chen C, *et al.* Low free testosterone and prostate cancer risk: a collaborative analysis of 20 prospective studies. Eur Urol **2018**;74:585-94
- 8. Watts EL, Fensom GK, Smith Byrne K, Perez-Cornago A, Allen NE, Knuppel A, *et al.* Circulating insulin-like growth factor-I, total and free testosterone concentrations and prostate cancer risk in 200,000 men in UK Biobank. **2020**:2020.03.27.20044941
- 9. Ruth KS, Day FR, Tyrrell J, Thompson DJ, Wood AR, Mahajan A, *et al.* Using human genetics to understand the disease impacts of testosterone in men and women. Nat Med **2020**;26:252-8
- 10. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, *et al.* Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer **2005**;12:1071-82
- 11. Key TJ, Appleby PN, Reeves GK, Travis RC, Brinton LA, Helzlsouer KJ, *et al.* Steroid hormone measurements from different types of assays in relation to body mass index and breast cancer risk in postmenopausal women: Reanalysis of eighteen prospective studies. Steroids **2015**;99:49-55
- 12. Allen NE, Key TJ, Dossus L, Rinaldi S, Cust A, Lukanova A, *et al.* Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer **2008**;15:485-97
- 13. Lukanova A, Lundin E, Micheli A, Arslan A, Ferrari P, Rinaldi S, *et al.* Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer **2004**;108:425-32

- 14. Ørsted DD, Nordestgaard BG, Bojesen SE. Plasma testosterone in the general population, cancer prognosis and cancer risk: a prospective cohort study. Ann Oncol **2014**;25:712-8
- 15. Seo JO, Yumnam S, Jeong KW, Kim SY. Finasteride inhibits melanogenesis through regulation of the adenylate cyclase in melanocytes and melanoma cells. Arch Pharm Res **2018**;41:324-32
- 16. Hu C, Fang D, Xu H, Wang Q, Xia H. The androgen receptor expression and association with patient's survival in different cancers. Genomics **2020**;112:1926-40
- 17. Aguirre-Portolés C, Payne R, Trautz A, Foskett JK, Natale CA, Ridky TW. Nonclassical testosterone signaling through ZIP9 renders melanoma more aggressive in males than in females. bioRxiv **2020**:2020.03.12.989160
- Gandini S, Iodice S, Koomen E, Di Pietro A, Sera F, Caini S. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis. Eur J Cancer 2011;47:2607-17
- Green J, Roddam A, Pirie K, Kirichek O, Reeves G, Beral V, *et al.* Reproductive factors and risk of oesophageal and gastric cancer in the Million Women Study cohort. Br J Cancer 2012;106:210-6
- Sinnott-Armstrong N, Naqvi S, Rivas M, Pritchard JK. GWAS of three molecular traits highlights core genes and pathways alongside a highly polygenic background. bioRxiv 2020:2020.04.20.051631
- Dwyer AA, Quinton R. Anatomy and Physiology of the Hypothalamic-Pituitary-Gonadal (HPG) Axis. In: Llahana S, Follin C, Yedinak C, Grossman A, editors. Advanced Practice in Endocrinology Nursing. Cham: Springer International Publishing; 2019. p 839-52.
- 22. Burger HG. Androgen production in women. Fertil Steril 2002;77:3-5
- Goldman AL, Bhasin S, Wu FCW, Krishna M, Matsumoto AM, Jasuja R. A reappraisal of testosterone's binding in circulation: physiological and clinical implications. Endocr Rev 2017;38:302-24
- 24. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, *et al.* UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS medicine **2015**;12:e1001779
- 25. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, *et al.* Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am J Epidemiol **2017**;186:1026-34
- 26. Elliott P, Peakman TC. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int J Epidemiol **2008**;37:234-44
- 27. Woods P, Owen JM. Designing and implementing a large-scale automated –80°C archive. Int J Epidemiol **2008**;37:i56-i61
- 28. Bartsch W. Interrelationships between sex hormone-binding globulin and testosterone, 5 alpha-dihydrotestosterone and oestradiol-17 beta in blood of normal men. Maturitas **1980**;2:109-18
- 29. UK Biobank. 2013 11/06/2020. Repeat assessment data. <<u>https://biobank.ctsu.ox.ac.uk/~bbdatan/Repeat assessment doc v1.0.pdf</u>>. 11/06/2020.
- 30. WHO. International statistical classification of diseases and related health problems. 10th revision. . **2010**
- 31. UK Biobank. 2019 Biomarker assay quality procedures: approaches used to minimise systematic and random errors (and the wider epidemiological implications). <<u>http://biobank.ctsu.ox.ac.uk/showcase/docs/biomarker issues.pdf</u>>.
- 32. Knuppel A, Fensom GK, Watts EL, Gunter MJ, Murphy N, Papier K, *et al.* Circulating insulin-like growth factor-I (IGF-I) concentrations and incidence of 30 cancers: prospective analyses in UK Biobank. Cancer Research **2020**;80:4014-21
- 33. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, *et al.* Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol **1999**;150:341-53
- 34. UK Biobank. 2013 Repeat assessment data. <<u>https://biobank.ctsu.ox.ac.uk/~bbdatan/Repeat_assessment_doc_v1.0.pdf</u>>.

- 35. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, *et al.* Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet **1990**;335:765-74
- 36. Plummer M. Improved estimates of floating absolute risk. Stat Med 2004;23:93-104
- 37. Noble WS. How does multiple testing correction work? Nat Biotechnol 2009;27:1135-7
- Cole-Clark D, Nair-Shalliker V, Bang A, Rasiah K, Chalasani V, Smith DP. An initial melanoma diagnosis may increase the subsequent risk of prostate cancer: Results from the New South Wales Cancer Registry. Sci Rep 2018;8:7167
- 39. Slominski A, Tobin DJ, Shibahara S, Wortsman J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol Rev **2004**;84:1155-228
- 40. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, *et al.* Effect of dutasteride on the risk of prostate cancer. N Engl J Med **2010**;362:1192-202
- 41. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, *et al.* The influence of finasteride on the development of prostate cancer. N Engl J Med **2003**;349:215-24
- 42. Kim J, Coetzee GA. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem **2004**;93:233-41
- 43. Wallis CJD, Krakowsky Y, Finelli A. Low Testosterone and Prostate Cancer: Is the Protection Real? Eur Urol **2018**;74:595-6
- 44. Tangen CM, Goodman PJ, Till C, Schenk JM, Lucia MS, Thompson IM, Jr. Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials. J Clin Oncol **2016**;34:4338-44
- 45. Fujihara Y, Hamanoue N, Yano H, Tanabe M, Akehi Y, Nomiyama T, *et al.* High sex hormone-binding globulin concentration is a risk factor for high fibrosis-4 index in middle-aged Japanese men. Endocr J **2019**;66:637-45
- 46. Sheh A, Ge Z, Parry NMA, Muthupalani S, Rager JE, Raczynski AR, *et al.* 17β-Estradiol and Tamoxifen Prevent Gastric Cancer by Modulating Leukocyte Recruitment and Oncogenic Pathways in Helicobacter Pylori–Infected INS-GAS Male Mice. Cancer Prev Res (Phila) 2011;4:1426-35
- 47. Ohtani M, Ge Z, García A, Rogers AB, Muthupalani S, Taylor NS, *et al.* 17 β-estradiol suppresses Helicobacter pylori-induced gastric pathology in male hypergastrinemic INS-GAS mice. Carcinogenesis **2011**;32:1244-50
- 48. Cheng CW, Chang CC, Patria YN, Chang RT, Liu YR, Li FA, *et al.* Sex hormone-binding globulin (SHBG) is a potential early diagnostic biomarker for gastric cancer. Cancer Med **2018**;7:64-74
- 49. Michels KA, Brinton LA, Wentzensen N, Pan K, Chen C, Anderson GL, *et al.* Postmenopausal Androgen Metabolism and Endometrial Cancer Risk in the Women's Health Initiative Observational Study. JNCI Cancer Spectrum **2019**;3:pkz029
- 50. Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer **1988**;57:205-12
- 51. Farhat GN, Cummings SR, Chlebowski RT, Parimi N, Cauley JA, Rohan TE, *et al.* Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Nat Cancer Inst **2011**;103:562-70
- Bleach R, McIlroy M. The Divergent Function of Androgen Receptor in Breast Cancer; Analysis of Steroid Mediators and Tumor Intracrinology. Front Endocrinol (Lausanne) 2018;9:594
- 53. Gibson DA, Simitsidellis I, Collins F, Saunders PTK. Evidence of androgen action in endometrial and ovarian cancers. Endocrine-Related Cancer **2014**;21:T203
- 54. Nunney L. Size matters: height, cell number and a person's risk of cancer. Proc Biol Sci 2018;285:20181743
- 55. Yuan T-A, Lu Y, Edwards K, Jakowatz J, Meyskens FL, Liu-Smith F. Race-, Age-, and Anatomic Site-Specific Gender Differences in Cutaneous Melanoma Suggest Differential

Mechanisms of Early- and Late-Onset Melanoma. Int J Environ Res Public Health 2019;16:908

- 56. Batty GD, Gale CR, Kivimäki M, Deary IJ, Bell S. Comparison of risk factor associations in UK Biobank against representative, general population based studies with conventional response rates: prospective cohort study and individual participant meta-analysis. BMJ 2020;368:m131
- 57. Handelsman DJ. Free testosterone: pumping up the tires or ending the free ride? Endocr Rev 2017;38:297-301

	Μ	len	Postmenopausal women		
		Incident cancer*		Incident cancer*	
	All (n=182,608)	(n=9,519)	All (n=122,112)	(n=5,632)	
Sociodemographic					
Age at recruitment (years), mean (SD)	56.13 (8.22)	61.07 (6.18)	60.15 (5.29)	61.29 (4.97)	
Most deprived quintile, % (N)	19.58 (35,716)	19.02 (1,808)	17.24 (21,037)	19.04 (1,072)	
Black ethnicity, % (N)	1.38 (2,485)	0.94 (88)	1.02 (1,238)	0.59 (33)	
Not in paid/self-employment, % (N)	36.52 (66,693)	53.50 (5,093)	54.93 (67,082)	60.58 (3,412)	
Living with partner, % (N)	76.91 (140,452)	77.08 (7,337)	69.48 (84,849)	67.86 (3,822)	
Anthropometric, mean (SD)					
Height (cm)	175.76 (6.82)	175.32 (6.70)	161.92 (6.19)	162.09 (6.32)	
BMI (kg/m^2)	27.61 (4.05)	27.69 (4.02)	26.96 (4.90)	27.53 (5.15)	
Lifestyle, % (N)					
Current cigarette smokers	12.53 (22,744)	15.14 (1,430)	7.90 (9,610)	10.77 (604)	
Drinking alcohol ≥20 g per day	44.37 (80,618)	46.38 (4,390)	13.50 (16,378)	14.61 (818)	
Low physical activity (0-10 METs per					
week)	27.32 (48,357)	27.64 (2,545)	30.83 (36,136)	32.82 (1,770)	
Health history, % (N)					
Hypertension	51.82 (94,587)	59.27 (5,637)	46.25 (56,422)	50.11 (2,817)	
Poor self-rated health	3.95 (7,164)	4.49 (425)	2.76 (3,355)	3.39 (190)	
Reproductive factors, % (N)					
Previous use of HRT	-	-	42.56 (51,965)	46.64 (2,627)	
Previous use of oral contraceptive pill	-	-	78.26 (95,570)	75.30 (4,241)	
Nulliparous	-	-	15.99 (19,514)	16.67 (938)	
<25 years at first child	-	-	55.06 (47,996)	57.96 (2,301)	
\geq 14 years at menarche	-	-	36.80 (43,619)	36.34 (1,984)	
<50 years at menopause	-	-	32.19 (33,439)	29.64 (1,401)	
Baseline blood measures, mean (SD)					
Free testosterone (pmol/L)	210.49 (59.54)	199.55 (54.92)	14.41 (10.13)	15.25 (10.59)	
Total testosterone (nmol/L)	12.11 (3.63)	11.97 (3.62)	1.09 (0.63)	1.14 (0.73)	
SHBG (nmol/L)	39.65 (16.51)	42.34 (17.21)	58.91 (26.51)	57.24 (26.00)	
Albumin (g/L)	45.59 (2.58)	45.06 (2.60)	45.11 (2.53)	44.85 (2.56)	

Table 1: Baseline characteristics and blood data in men and postmenopausal women (in the analytic sample and incident cancers cases) in UK Biobank

* Diagnosed > 2 years from baseline

Abbreviations: BMI=body mass index; HRT= hormone replacement therapy; METs=metabolic equivalent of tasks; SD=standard deviation; SHBG=sex hormone binding globulin

Figure legends

Figure 1: HRs and 95% CIs for cancer diagnosis per increment in free testosterone, total testosterone and SHBG concentrations by cancer site in men⁺

HRs are presented by squares with their 95% CIs as horizontal lines, the size of the squares is inversely proportional to the variance of the log HR. P_{trends} are bold if associations are statistically significant after accounting for false discovery rates. *Increments are free testosterone, per 50 pmol/L; total testosterone, per 5 nmol/L; SHBG, per 10 nmol/L.

[†]Associations stratified for age group, geographical region and adjusted for Townsend deprivation score, racial/ethnic group, height, lives with a spouse or partner, body mass index, cigarette smoking, alcohol consumption, and total physical activity and corrected for regression dilution bias.

Abbreviations: CI=Confidence interval; HR=hazard ratio; SHBG= sex hormone binding globulin.

Figure 2: HRs and 95% CIs for cancer diagnosis per increment in free testosterone, total testosterone and SHBG concentrations by cancer site in postmenopausal women[†]

HRs are presented by squares with their 95% CIs as horizontal lines, the size of the squares is inversely proportional to the variance of the log HR. P_{trends} are bold if associations are statistically significant after accounting for false discovery rates. *Increments are free testosterone, per 10 pmol/L; total testosterone, per 0.5 nmol/L; SHBG, per 25 nmol/L. †Associations stratified for age group, geographical region and adjusted for Townsend deprivation score, racial/ethnic group, height, lives with a spouse or partner, body mass index, cigarette smoking, alcohol consumption, total physical activity, hormone replacement therapy use, oral contraceptive use, and parity and age at first birth, and corrected for regression dilution bias.

Abbreviations: CI=Confidence interval; HR=hazard ratio; SHBG=sex hormone binding globulin.

Figure 3: HRs and 95% CIs per increment in free testosterone, total testosterone and SHBG for cancer diagnosis by cancer site and time to diagnosis in men⁺

HRs are presented by squares with their 95% CIs as horizontal lines, the size of the squares is inversely proportional to the variance of the log HR. HRs are presented by squares with their 95% CIs as horizontal lines, the size of the squares is inversely proportional to the variance of the log HR. $P_{\text{heterogeneity}}$ (Phet) comparing associations below and above time to diagnosis obtained using competing risks, p-values are bold if p<0.05.

*Increments are free testosterone, per 50 pmol/L; total testosterone, per 5 nmol/L; SHBG, per 10 nmol/L.

*Associations stratified for age group, geographical region and adjusted for Townsend deprivation score, racial/ethnic group, height, lives with a spouse or partner, body mass index, cigarette smoking, alcohol consumption and total physical activity. Follow-up time was based on the median time to diagnosis.

Abbreviations: CI=Confidence interval; HR=hazard ratio; SHBG= sex hormone binding globulin.

Figure 4: HRs and 95% CIs per free testosterone, total testosterone and SHBG increment for cancer diagnosis by cancer site and time to diagnosis in postmenopausal women[†]

HRs are presented by squares with their 95% CIs as horizontal lines, the size of the squares is inversely proportional to the variance of the log HR. HRs are presented by squares with their 95% CIs as horizontal lines, the size of the squares is inversely proportional to the variance of the log HR. $P_{\text{heterogeneity}}$ (Phet) comparing associations below and above time to diagnosis obtained using competing risks, p-values are bold if p<0.05.

*Increments are free testosterone, per 10 pmol/L; total testosterone, per 0.5 nmol/L; SHBG, per 25 nmol/L.

[†]Associations stratified for age group, geographical region and adjusted for Townsend deprivation score, racial/ethnic group, height, lives with a spouse or partner, body mass index, cigarette smoking, alcohol consumption, total physical activity, hormone replacement therapy use, oral contraceptive use, and parity and age at first birth. Follow-up time was based on the median time to diagnosis.

Abbreviations: CI=Confidence interval; HR=hazard ratio; SHBG= sex hormone binding globulin.

Cancer site	Cases		HR per increment* (95% CI)	P trend
Free testosterone (total n=167,938)				
Malignant melanoma (C43)	469	<u> </u>	1.35 (1.14, 1.61)	0.0006
Multiple myeloma (C90)	147		1.33 (0.98, 1.82)	0.0711
Mesothelioma (C45)	112		1.30 (0.91, 1.85)	0.1557
Prostate (C61)	3550	-	1.10 (1.04, 1.18)	0.0024
Pancreas (C25)	199		1.04 (0.79, 1.37)	0.7761
Adenocarcinoma, esophagus (C15)	173		1 03 (0 76, 1 38)	0.8611
Brain (C71)	163		1 02 (0 75, 1 37)	0.9043
Colorectum (C18-20)	1042		$0.97 (0.86 \ 1.09)$	0.5667
Kidnev (C64-65)	298		0.93 (0.74, 1.16)	0 5153
Bladder (C67)	259		0.92 (0.72, 1.18)	0.5034
Non-Hodgkin lymphoma (C82-85)	368		0.91 (0.75, 1.12)	0.3882
Luna (C34)	656	_ _	0.90(0.77, 1.05)	0 1641
Oral (C00-14)	229		0.84 (0.65, 1.09)	0 1851
Stomach (C16)	139		0.80 (0.57, 1.12)	0.1001
Leukemia (C91-95)	266		0.77 (0.60, 0.99)	0.0386
Liver (C22)	96		0.69(0.45, 1.05)	0.0848
2.00. (022)	50		0.00 (0.40, 1.00)	0.0040
Total testosterone (total n=182,608)				
Liver (C22)	100		2.45 (1.56, 3.84)	0.0001
Mesothelioma (C45)	126		- 1.63 (1.10, 2.42)	0.0157
Malignant melanoma (C43)	522		1.28 (1.05, 1.55)	0.015
Stomach (C16)	152		1.11 (0.77, 1.60)	0.5864
Bladder (C67)	285		0.99 (0.76, 1.30)	0.9495
Prostate (C61)	3845	_ _	0.99 (0.92, 1.06)	0.6957
Pancreas (C25)	213		0.98 (0.72, 1.34)	0.9107
Adenocarcinoma, esophagus (C15)	192		0.95 (0.68, 1.33)	0.7767
Lung (C34)	705	_ _	0.92 (0.77, 1.09)	0.3179
Kidnev (C64-65)	329		0.91 (0.71, 1.18)	0 4743
Non-Hodgkin lymphoma (C82-85)	408		0.89(0.71, 1.12)	0.3228
Multiple myeloma (C90)	163		0.88(0.61, 1.26)	0 4728
Colorectum (C18-20)	1124		0.88(0.76, 1.01)	0.0594
Brain (C71)	189		0.78 (0.56, 1.09)	0 1517
Leukemia (C91-95)	285		0.78 (0.59, 1.02)	0.0681
Oral (C00-14)	245		0.76 (0.57, 1.02)	0.0699
SUBC (total n=168 835)				
Liver (C22)	07		1 56 (1 31 1 97)	~0 0001
Stomach (C16)	1/3		1.30 (1.31, 1.37)	0.0077
Mesothelioma (C45)	140		1.21(1.05, 1.40)	0.0077
Adenocarcinoma, esonhagus (C15)	175		1.07 (0.04, 1.21)	0.101
Lung (C34)	659		1.07 (0.84, 1.21)	0.3047
Bladder (C67)	260	<u> </u>	1.03 (0.90, 1.10)	0.309
Non-Hodakin lymphoma (C82-85)	200		1.01 (0.92, 1.12)	0.0074
Pancreas (C25)	100	<u> </u>	1.00 (0.82, 1.10)	0.0007
Oral (C00-14)	230		1.00 (0.89, 1.13)	0.991
Malignant melanoma (C/3)	472			0.3402
	472		0.99(0.91, 1.07)	0.7202
Kidney (C64-65)	207			0.4020
Colorectum (C18-20)	300			0.2139
$\frac{1}{2}$	1047			0.0184
$\frac{1}{10000}$	30/0			\U.UUU1
Multiple myeloma (C90)	100	_ _T	U.33 (U.82, 1.00)	0.2007
	147		0.09 (0.77, 1.02)	0.0953
		0.5 1 2	4	
		HR per increment* (95% C	1)	

Cancer site	Cases		HR per increment* (95% CI)	P trend
Free testosterone (total n=110,628)				
Endometrial (C54.1)	370	_	1.59 (1.32, 1.90)	<0.0001
Stomach (C16)	42		— 1.40 (0.81, 2.41)	0.2281
Kidney (C64-65)	102		1.35 (0.96, 1.91)	0.0844
Breast (C50)	1862		1.32 (1.22, 1.43)	<0.0001
Brain (C71)	74		1.18 (0.78, 1.77)	0.4318
Lung (C34)	407	↓	1.15 (0.97, 1.37)	0.1145
Pancreas (C25)	123		1.14 (0.83, 1.57)	0.4088
Bladder (C67)	57		1.12 (0.70, 1.80)	0.6257
Mesothelioma (C45)	23		- 1.10 (0.50, 2.39)	0.8158
Oral (C00-14)	78		1.09 (0.73, 1.64)	0.6738
Liver (C22)	48		1 05 (0.63, 1.75)	0.8538
Malignant melanoma (C43)	264		0.96 (0.77, 1.20)	0 7348
Ovarian (C56)	228		0.95(0.75, 1.20)	0 6474
Leukemia (C91-95)	113		0.94(0.67, 1.20)	0.7196
Colorectum (C18-20)	567	_	0.90(0.77, 1.02)	0.1638
Adenocarcinoma, esophagus (C15)	34		0.87(0.47, 1.64)	0.6608
Non-Hodgkin lymphoma (C82-85)	209		0.76 (0.59, 0.99)	0.0000
Multiple myeloma (C90)	203		0.65 (0.43, 0.93)	0.0348
	02		0.03 (0.43, 0.97)	0.0340
Total testosterone (total n=122,112)				
Stomach (C16)	46		1.42 (0.98, 2.06)	0.0669
Endometrial (C54.1)	402	_ _	1.34 (1.18, 1.52)	<0.0001
Liver (C22)	54		1.29 (0.92, 1.82)	0.1433
Pancreas (C25)	139	_	1.25 (1.01, 1.55)	0.0385
Breast (C50)	2041		1.24 (1.17, 1.31)	<0.0001
Leukemia (C91-95)	129	_	1.13 (0.90, 1.41)	0.2944
Kidney (C64-65)	115		1 12 (0 89 1 42)	0.3328
Bladder (C67)	60		1.06 (0.76, 1.47)	0.7253
Brain (C71)	82		1.06 (0.80, 1.41)	0.6845
Lung (C34)	453		1.00 (0.89, 1.13)	0.0040
Mesothelioma (C45)	-99	Ţ	1.00 (0.60, 1.67)	0.0007
Oral (C00-14)	81		0.97 (0.73, 1.28)	0.8073
$O_{\text{varian}}(C56)$	252		0.97 (0.73, 1.20)	0.0073
Malignant melanoma (C43)	200		0.95 (0.87, 1.12)	0.3707
Non-Hodgkin lymphoma (C82-85)	292		0.95 (0.82, 1.10)	0.4033
Colorectum (C18.20)	235		0.95(0.80, 1.12)	0.5265
Adenagarcingma, acenhagua (C15)	610		0.95 (0.85, 1.05)	0.200
Adenocarcinoma, esophagus (C13)	34		0.76 (0.49, 1.20)	0.2455
Multiple myeloma (C90)	96	-	0.73 (0.56, 0.96)	0.0228
SHBG (total n=111,170)				
Liver (C22)	49		1.30 (0.89, 1.90)	0.1777
Bladder (C67)	57		1.23 (0.87, 1.76)	0.2457
Multiple myeloma (C90)	82		1.16 (0.86, 1.56)	0.339
Ovarian (C56)	229		1.12 (0.94, 1.33)	0.2245
Non-Hodgkin lymphoma (C82-85)	210		1.09 (0.90, 1.31)	0.3836
Colorectum (C18-20)	572	+ - -	1.08 (0.96, 1.21)	0.1867
Malignant melanoma (C43)	266	_	1.07 (0.91, 1.26)	0.436
Pancreas (C25)	123	_	1.02 (0.80, 1.30)	0.8668
Leukemia (C91-95)	114		0.99 (0.77, 1.28)	0.9578
Lung (C34)	407		0.98(0.85, 1.12)	0 7333
Oral (C00-14)	78		0.98(0.72, 1.33)	0.8785
Brain (C71)	70		0.97 (0.70, 1.33)	0.8275
Mesothelioma (C45)	74 23		0.94 (0.54, 1.66)	0.0273
Stomach (C16)	20			0.0410
Breast (C50)	42			0.0020
Adenocarcinoma, coophague (C15)	10/0		0.00 (0.03, 0.94)	0.0002
Endomotrial (C54.1)	30		0.00 (0.54, 1.42)	0.0903
	372		0.78 (0.67, 0.91)	0.0014
Nulley (004-00)	102		U.78 (U.59, 1.U3)	0.0763
		0.5 1 1.5 2	2.5	

HR per increment* (95% CI)

Cancer site	Cases	>2 - ≤4.7 years HR	per increment* (95% CI)	Cases	>4.7 years	HR per increment* (95% CI)	P het
Free testosterone (total n=167,938)							
Malignant melanoma (C43)	207	 _	1.20 (0.92, 1.56)	262		1.49 (1.18, 1.88)	0.2183
Multiple myeloma (C90)	70		1 39 (0 88, 2 18)	77		1 29 (0 84, 1 99)	0.8256
Mesothelioma (C45)	55		1 33 (0 80, 2 22)	57		1 26 (0.76, 2.08)	0.8712
Adenocarcinoma, esonhagus (C15)	90		0.80 (0.50, 1.36)	83		1.20 (0.70, 2.00)	0.3257
Non Hodgkin lymphoma (C82,85)	30		0.09(0.59, 1.50)	05		1.20 (0.79, 1.04)	0.3237
Prostate (C61)	1705		0.05 (0.54, 1.55)	4705		1.19 (0.79, 1.79)	0.2750
	1765		1.06 (0.97, 1.16)	1785		1.15 (1.05, 1.26)	0.2207
Paricieas (C25)	85		0.95 (0.62, 1.45)	114		1.11 (0.77, 1.59)	0.5887
Oral (C00-14)	65		0.53 (0.32, 0.88)	59		1.02 (0.62, 1.67)	0.0695
Lung (C34)	327		0.82 (0.66, 1.02)	329		0.98 (0.79, 1.21)	0.2738
Colorectum (C18-20)	539	-+-	1.00 (0.85, 1.18)	503		0.93 (0.78, 1.11)	0.5671
Kidney (C64-65)	144		0.96 (0.69, 1.33)	154		0.90 (0.66, 1.24)	0.7969
Brain (C71)	189		0.95 (0.72, 1.26)	179		0.88 (0.65, 1.18)	0.7009
Bladder (C67)	127	-+	0.99 (0.70, 1.40)	132		0.86 (0.60, 1.22)	0.5708
Leukemia (C91-95)	127		0.71 (0.50, 1.02)	139	— — ——————————————————————————————————	0.83 (0.59, 1.16)	0.5461
Liver (C22)	43		0.62 (0.32, 1.18)	53		0.76 (0.44, 1.32)	0.6333
Stomach (C16)	74		0.85 (0.53, 1.35)	65		0.73 (0.44, 1.21)	0.6663
Total testosterone (total n=182.608)							
Liver (C22)	43		3 37 (1 69 6 70)	57		- 1 91 (1 05 3 46)	0 2211
Mesothelioma (C45)	60	´	1 94 (1 09, 3 44)	66		1 40 (0 81 2 43)	0 4208
Malignant melanoma (C43)	229		1 21 (0 90, 1 63)	293		1 33 (1 03, 1 73)	0.6302
Pancreas (C25)	93		0.68 (0.42, 1.11)	120		1 28 (0 85, 1 92)	0.0535
Non-Hodgkin lymphoma (C82-85)	87		0.00 (0.42, 1.11)	102		1 21 (0 78, 1 89)	0.0000
Stomach (C16)	79		1 10 (0 66, 1 83)	73		1 10 (0.65, 1.88)	0.000
Bladder (C67)	1/1		0.97 (0.66, 1.42)	144		1.02 (0.69, 1.00)	0.8554
Prostate (C61)	1021		0.97 (0.00, 1.42)	1924	1	1.02 (0.03, 1.43)	0.000-
Leukemia (C91-95)	1321]	0.57(0.07, 1.07)	151	<u>I</u>	0.89 (0.61, 1.29)	0.0022
Colorectum (C18-20)	570		0.07 (0.43, 1.00) 0.97 (0.72, 1.05)	545		0.89 (0.73, 1.29)	0.3039
Lung (C34)	379]	0.07 (0.72, 1.03)	343		0.89 (0.73, 1.08)	0.0902
Kidpov (C64 65)	160		0.97 (0.70, 1.24)	335		0.86 (0.60, 1.10)	0.4943
Oral (C00, 14)	70		0.97 (0.67, 1.39)	169		0.86 (0.80, 1.23)	0.047
Adapagargingma, apophagua (C15)	72		0.72 (0.42, 1.25)	81		0.80 (0.44, 1.43)	0.0145
Adenocarcinoma, esopriagus (CTS)	99		1.15 (0.73, 1.81)	93		0.79 (0.49, 1.29)	0.2755
Brain (C71)	213		1.03 (0.75, 1.40)	195	— —	0.76 (0.55, 1.06)	0.1969
Multiple myeloma (C90)	11		1.14 (0.68, 1.90)	86		0.69 (0.41, 1.14)	0.1714
SHBG (total n=168,835)							
Liver (C22)	43		1.92 (1.45, 2.55)	54		1.32 (1.05, 1.67)	0.0449
Stomach (C16)	75		1.23 (1.01, 1.49)	68	⊢	1.20 (0.97, 1.47)	0.8558
Pancreas (C25)	85	- - +	0.88 (0.73, 1.06)	114	- +-	1.09 (0.94, 1.28)	0.0752
Bladder (C67)	128	-+-	0.99 (0.86, 1.15)	132	- - -	1.04 (0.89, 1.20)	0.6732
Mesothelioma (C45)	55		1.24 (0.98, 1.56)	57	-+	1.01 (0.81, 1.26)	0.2105
Brain (C71)	189	+	1.02 (0.90, 1.15)	180	-+-	1.00 (0.88, 1.14)	0.875
Adenocarcinoma, esophagus (C15)	92		1.14 (0.96, 1.36)	83	-+-	0.99 (0.83, 1.19)	0.2705
Non-Hodgkin lymphoma (C82-85)	76	- - +	0.87 (0.72, 1.06)	87	-4-	0.99 (0.82, 1.18)	0.351
Lung (C34)	329	 _	1.08 (0.98, 1.18)	330		0.99 (0.90, 1.08)	0.1999
Malignant melanoma (C43)	208	+	1.00 (0.89, 1.12)	264	-4-	0.98 (0.88, 1.09)	0.8139
Kidney (C64-65)	145		0.93 (0.80, 1.06)	155		0.95 (0.83, 1.09)	0.758
Leukemia (C91-95)	127		0.98 (0.84, 1.14)	140		0.95 (0.83, 1.10)	0.8013
Prostate (C61)	1784		0.94 (0.90, 0.98)	1791		0.93 (0.89, 0.96)	0.5791
Colorectum (C18-20)	543	4	0.95 (0.89, 1.02)	504	-	0.93 (0.86, 1.00)	0.607
Oral (C00-14)	66		1.11 (0.90, 1.36)	59	_ •+	0.87 (0.69, 1.09)	0.1263
Multiple myeloma (C90)	70	_ + _	0.99 (0.81, 1.21)	77	_ _	0.80 (0.66, 0.98)	0.1508
		0.25 0.5 1 2 3 4 5	-	0.25	0.5 1 2 3	3 4 5	
		HR per increment* (95% CI)		5.25	HR per increment* (95% C	D	
						-7	

Cancer site	Cases	>2 - ≤4.7 years	HR per increment* (95% CI)	Cases	>4.7 years	HR per increment* (95% CI)	P het
Free testosterone (total n=110,628)					1		
Endometrial (C54.1)	197	_	1.65 (1.29, 2.11)	173		1.52 (1.17, 1.99)	0.6701
Breast (C50)	939	-	1 28 (1 14 1 43)	923		1.36 (1.22, 1.53)	0 4409
Stomach (C16)	Insufficient data		1.20 (1111, 1110)	28		1 32 (0 68, 2 58)	-
Kidney (C64-65)	5/		1 42 (0 89 2 26)	48		1 29 (0 78 2 14)	0 7831
Liver $(C22)$	J4 Incufficient data		1.42 (0.09, 2.20)	10		1.29 (0.76, 2.14)	0.7031
Ord(C22)			4 04 (0 57 4 70)	20		1.26 (0.65, 2.44)	-
Colorectum (C18, 20)	40		1.01 (0.57, 1.78)	38		1.21 (0.67, 2.16)	0.0093
Colorectum (CT6-20)	289	_	0.68 (0.55, 0.85)	278		1.17 (0.95, 1.45)	0.0006
Brain (C71)	30		1.27 (0.67, 2.41)	44		1.15 (0.68, 1.95)	0.8185
Lung (C34)	184	+	1.16 (0.89, 1.50)	223	+	1.15 (0.90, 1.45)	0.9595
Malignant melanoma (C43)	120		0.92 (0.66, 1.28)	144		1.00 (0.74, 1.35)	0.7057
Bladder (C67)	33		1.22 (0.65, 2.27)	24		0.99 (0.48, 2.04)	0.6727
Non-Hodgkin lymphoma (C82-85)	107	<u> </u>	0.59 (0.41, 0.87)	102		0.96 (0.67, 1.38)	0.0696
Pancreas (C25)	60		1.38 (0.88, 2.16)	63		0.95 (0.60, 1.49)	0.2516
Ovarian (C56)	123		0.96 (0.69, 1.33)	105		0.93 (0.66, 1.32)	0.9184
Leukemia (C91-95)	61		0.99 (0.62, 1.57)	52		0.88(0.53, 1.46)	0 7467
Multiple myeloma (C90)	13		0.46 (0.25, 0.85)	30		0.86 (0.49, 1.52)	0.1421
Adonacarcinoma, osonbagus (C15)	40 Incufficient data		0.40 (0.23, 0.03)	Jogufficient dete		0.00 (0.49, 1.02)	0.1421
Monothaliama (C4E)							-
Mesothelioma (C45)	Insufficient data			Insufficient data			-
Total testosterone (total n=122 112)							
Liver (C22)	22		4 40 (0 65 4 00)	20		1 11 (0 00 0 0 05)	0 4007
Endemotrial (CE4.1)	22		1.12 (0.65, 1.93)	32		1.44 (0.92, 2.25)	0.4837
Endometrial (C54.1)	215		1.39 (1.17, 1.65)	187		1.28 (1.07, 1.54)	0.5371
Stomach (C16)	Insufficient data			30	- -	1.28 (0.81, 2.04)	-
Breast (C50)	1021	+	1.22 (1.13, 1.32)	1020	■	1.25 (1.16, 1.36)	0.6339
Pancreas (C25)	66		1.32 (0.97, 1.80)	73		1.20 (0.89, 1.61)	0.6489
Leukemia (C91-95)	68	-	1.09 (0.80, 1.49)	61		1.16 (0.84, 1.61)	0.7853
Bladder (C67)	36		1.01 (0.66, 1.54)	24		1.12 (0.67, 1.87)	0.754
Colorectum (C18-20)	318	_ - _	0.81 (0.70, 0.94)	292	+ - -	1 11 (0 96 1 29)	0.0032
Non-Hodgkin lymphoma (C82-85)	121		0.83 (0.65, 1.05)	114		1.08 (0.85, 1.20)	0.1231
Kidpov (C64.65)	62	-		F 2	_	1.05 (0.33, 1.37)	0.1201
	02		1.19 (0.00, 1.04)	53		1.05 (0.74, 1.49)	0.5976
Lung (C34)	204	_	1.05 (0.88, 1.25)	249		0.97 (0.82, 1.14)	0.5045
Brain (C/1)	34		1.24 (0.80, 1.92)	48		0.95 (0.65, 1.38)	0.3607
Malignant melanoma (C43)	135		0.97 (0.78, 1.21)	157		0.93 (0.76, 1.14)	0.7872
Ovarian (C56)	137	_ + _	1.01 (0.81, 1.25)	116	-+-	0.90 (0.71, 1.14)	0.4913
Oral (C00-14)	42		1.06 (0.72, 1.58)	39		0.88 (0.58, 1.34)	0.5143
Multiple myeloma (C90)	50	<u> </u>	0.62 (0.42, 0.91)	46		0.85 (0.58, 1.25)	0.2425
Adenocarcinoma, esophagus (C15)	Insufficient data			Insufficient data			-
Mesothelioma (C45)	Insufficient data			Insufficient data			-
SHBG (total n=111,170)							
Bladder (C67)	33		1.13 (0.71, 1.81)	24		1.41 (0.81, 2.44)	0.5557
Liver (C22)	Insufficient data			29		1.35 (0.81, 2.24)	-
Pancreas (C25)	60	_	0.88 (0.62, 1.26)	63	_ _	1.18 (0.84, 1.65)	0.2514
Non-Hodgkin lymphoma (C82-85)	108		1.07 (0.83, 1.39)	102		1.10 (0.85, 1.44)	0.8805
Multiple myeloma (C90)	43		1 23 (0 82 1 84)	39		1.09 (0.69, 1.70)	0.687
Colorectum (C18-20)	201		1 11 (0 95, 1 30)	281		1.05 (0.89, 1.23)	0.6076
Malignant melanoma (C43)	101		1 10 (0.87, 1.41)	145		1.03 (0.83, 1.23)	0.0070
Overien (C56)	121		1.10 (0.07, 1.41)	140		1.04 (0.83, 1.30)	0.7259
Ovariari (C56)	123		1.19 (0.94, 1.51)	106		1.03 (0.79, 1.34)	0.4174
	61		1.02 (0.72, 1.44)	53		0.96 (0.66, 1.38)	0.8061
Oral (C00-14)	40		1.01 (0.66, 1.54)	38		0.94 (0.61, 1.46)	0.8303
Stomach (C16)	Insufficient data			28		0.94 (0.56, 1.56)	-
Lung (C34)	184	- +-	1.09 (0.89, 1.33)	223	-++	0.90 (0.75, 1.08)	0.1601
Breast (C50)	942	-=-	0.91 (0.83, 1.00)	928	-=-	0.86 (0.78, 0.94)	0.3368
Brain (C71)	30		1.14 (0.70, 1.87)	44		0.85 (0.55. 1.29)	0.3615
Kidnev (C64-65)	54		0.80 (0.54, 1.18)	48		0.75(0.50, 1.13)	0.8252
Endometrial (C54 1)	199		0.83 (0.68, 1.02)	173		0.71 (0.56, 0.90)	0 3383
Adenocarcinoma esonbagus (C15)	Insufficient data	-	0.00 (0.00, 1.02)	Insufficient date		0.7 1 (0.00, 0.00)	-
Mosotholioma (C45)				Insufficient data			-
wesourenoma (C45)	insuncient data		_11	insunicient data			-
		0.25 0.5 1 2	3 4	C	0.25 0.5 1 2 3	3 4	
		HR per increment* (95% CI)			HR per increment* (95% CI)		